



Published in final edited form as:

Curr Psychiatry Rep. 2016 August ; 18(8): 70. doi:10.1007/s11920-016-0709-y.

Concurrent Treatment of Substance Use and PTSD

Julianne C. Flanagan¹, Kristina J. Korte¹, Therese K. Killeen¹, and Sudie E. Back^{1,2}

¹Medical University of South Carolina, 5 Charleston Center Drive, Suite 151, Charleston, SC 29455, USA

²Ralph H. Johnson VAMC, 109 Bee St, Charleston, SC 29401, USA

Abstract

Substance use disorders (SUD) and posttraumatic stress disorder (PTSD) are chronic, debilitating conditions that frequently co-occur. Individuals with co-occurring SUD and PTSD suffer a more complicated course of treatment and less favorable treatment outcomes compared to individuals with either disorder alone. The development of effective psychosocial and pharmacological interventions for co-occurring SUD and PTSD is an active and critically important area of investigation. Several integrated psychosocial treatments for co-occurring SUD and PTSD have demonstrated promising outcomes. While recent studies examining medications to treat co-occurring SUD and PTSD have yielded encouraging findings, there remain substantial gaps in the evidence base regarding the treatment of co-occurring SUD and PTSD. This review will summarize the findings from clinical trials targeting a reduction in SUD and PTSD symptoms simultaneously. These results may improve our knowledge base and subsequently enhance our ability to develop effective interventions for this complex comorbid condition.

Keywords

Substance use disorders; Addiction; Posttraumatic stress disorder; Clinical trials; Integrated intervention

Introduction

Overview

Extensive literature documents a strong association between substance use disorders (SUD) and posttraumatic stress disorder (PTSD) [1–3]. Epidemiological data indicate that approximately 30 % of the general US population will experience SUD and 8 % will experience PTSD during their lifetime [4]. PTSD co-occurs with SUD among roughly 40 % of civilians and veterans [2, 5, 6]. Individuals with co-occurring SUD and PTSD incur heightened risk for other psychiatric problems (e.g., depression, anxiety), suicidality,

[✉]Julianne C. Flanagan, Hellmuth@musc.edu.

Compliance with Ethical Standards

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest The authors declare that they have no conflict of interest.

neuropsychological impairment, increased morbidity and mortality, unemployment, and social impairment [2, 5, 7, 8]. This complex comorbidity also places a tremendous economic burden on the healthcare system, as it results in poorer treatment outcomes, longer duration of substance use, and more treatment episodes [9–12].

While several theories have been proposed to explain the common co-occurrence of SUD and PTSD, the self-medication theory has received the most empirical support to date [13]. This theory posits that individuals with PTSD incur a heightened risk for substance use and developing substance use disorders due to their propensity to drink alcohol or use drugs to mitigate the distressing symptoms and sequelae of PTSD. Support for this theory has been garnered by studies demonstrating that PTSD typically emerges before co-occurring substance use disorders [14, 15] as well as evidence indicating that PTSD symptom management is a primary rationale for substance use among individuals with co-occurring SUD and PTSD [16, 17].

Despite the significant impairment, distress, and clinical complications associated with co-occurring SUD and PTSD, effective treatments for this comorbid condition are still in the nascent stage. Ongoing controversies that have informed treatment development efforts for co-occurring SUD and PTSD question the safety of (1) integrated psychosocial modalities which treat SUD and PTSD concurrently, (2) the use of exposure-based psychosocial modalities in particular, and (3) application of pharmacotherapies in comorbid populations. Early approaches to the treatment of co-occurring SUD and PTSD followed the “sequential model”, which requires patients to establish and maintain abstinence from substance use before initiating trauma-focused treatment. Adherence to the sequential model historically stemmed from concerns that trauma-focused treatments would lead to a worsening of SUD in those with PTSD. Indeed, providers treating individuals with co-occurring PTSD and SUD face a formidable challenge. Data indicate that providers often view co-occurring SUD and PTSD have difficulty prioritizing and integrating treatment approaches to successfully meet patients’ needs [18]. Providers also commonly express concern that integrated treatment may exacerbate symptoms.

Over time, the literature indicating the safety, acceptability, and efficacy of integrated psychosocial interventions for co-occurring SUD and PTSD has grown [19–21]. Data also indicates that many patients prefer to engage in integrated, rather than sequential, models of treatment [22, 23]. As a result, several integrated psychosocial treatments have been developed to treat SUD and PTSD concurrently [24, 25]. Investigators are also actively pursuing the development of pharmacological treatments [26, 27] and the use of combined psychosocial and pharmacological treatment approaches [28, 29] to treat co-occurring SUD and PTSD.

This review will provide a description of psychosocial, pharmacological, and combined interventions that have been examined to treat co-occurring SUD and PTSD. We will review evidence-based psychosocial treatments including those grounded in exposure approaches, integrated treatment modalities which do not utilize exposure approaches, and pharmacological interventions that have been tested to treat SUD and PTSD concurrently.

Exposure-Based Treatments for Co-occurring SUD and PTSD

Prolonged Exposure (PE) is a highly efficacious, evidence-based, cognitive-behavioral therapy for PTSD [30]. Although some studies have included individuals with SUD in clinical trials examining the efficacy of PE to treat PTSD, findings regarding the effect of PE on substance use have not typically been reported [31–33]. One study by Schnurr and colleagues reported on the impact of PE on SUD symptoms as a secondary outcome in a study examining the use of PE in comparison to present centered therapy in a sample of female veterans [34]. Despite reductions in PTSD symptoms, there were no significant changes in substance use outcomes at either post-treatment or the six month follow-up. Similarly, Pacella and colleagues reported no significant reductions in substance use in a sample of HIV patients receiving PE [35].

There has been a recent increase in studies examining the efficacy of integrated treatments that combine PE with cognitive-behavioral SUD approaches. Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE) [36] is one such modality that synthesizes empirically-validated cognitive-behavioral treatment for SUD with PE. Back and colleagues first reported in detail on the acceptability and feasibility of using COPE through a case study on an Iraq Veteran with PTSD and co-occurring alcohol use disorder [37]. Mills and colleagues conducted a randomized clinical trial of COPE among Australian civilians and found COPE to be superior in reducing PTSD and substance use symptoms compared to treatment-as-usual [24•]. Recently, Back and colleagues completed a randomized clinical trial evaluating the efficacy of COPE among Veterans. Participants were randomized to receive COPE or cognitive-behavioral relapse prevention [38]. Preliminary results indicate significant reductions in SUD and PTSD symptoms, and indicate that reductions in PTSD symptoms during treatment account for more than half of the variance in substance use reduction [39•]. Replication will be needed to provide additional support for the efficacy for this novel and promising approach, especially as it relates to dissemination and implementation in across treatment settings.

Existing literature suggests that treating co-occurring SUD and PTSD using exposure-based approaches such as PE is safe, acceptable, and effective. Nevertheless, there remain substantial gaps in the literature and further investigations examining the use of exposure-based integrated treatments alone and in combination with pharmacotherapies are needed to more fully discern the efficacy of these approaches and considerations for modifying treatments for subpopulations with specific treatment needs.

Non-exposure-Based Treatments for SUD and PTSD

The majority of studies to date have investigated non-exposure-based psychosocial interventions for the treatment of co-occurring SUD and PTSD. Although exposure-based treatments are highly effective in reducing PTSD, there is reluctance among some clinicians and researchers to employ exposure-based methods to treat PTSD among patients presenting with a comorbid SUD. Similar to the previously noted reservations regarding integrated modalities for co-occurring SUD and PTSD, this reluctance is due mainly to anecdotal concerns that substance use during treatment would impede therapeutic efforts, and that exposure-based trauma work would result in increased substance use and/or relapse [40, 41].

Over the past decade, however, a growing body of empirical research has demonstrated that like exposure-based treatments, non-exposure-based treatments are also safe and effective to use among patients with co-occurring SUD and PTSD.

As indicated by the title, non-exposure-based treatments exclude exposure to the trauma memory (i.e., no imaginal exposure) or exposure to stimuli that are safe, but avoided because they are reminders of the trauma (i.e., no in vivo exposure). Rather, non-exposure-based treatments focus on topics such as psychoeducation, the relationship between substance use and PTSD symptoms, enhancing coping skills, managing negative emotions, and exploring the impact of trauma symptoms.

The most widely used and investigated non-exposure-based treatment to date is *Seeking Safety* (SS), a 24-session manualized therapy that focuses on establishing and maintaining safety [25, 42, 43•]. Topics include, for example, detaching from emotional pain, asking for help, compassion, honesty, integrating the split self, community resources, setting boundaries in relationships, coping with triggers, self-nurturing, and recovery thinking. Hien and colleagues compared SS to relapse prevention in a community sample of women ($N = 107$) with SUD and PTSD or sub-threshold PTSD [25]. Patients were randomly assigned and then completed individual sessions twice weekly for 12 weeks. No significant differences in SUD or PTSD symptoms were observed between the SS and relapse prevention group. In addition, PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS) at post-treatment remained in the moderately severe range (total score range 48–60). In a larger multisite community study, Hien and colleagues compared SS to a women's health education (WHE) control group among 353 women [43•]. Patients were randomized to 12 twice-weekly sessions of SS or WHE delivered in a group format. The results showed that PTSD symptoms significantly reduced in both groups with no between-groups difference. Neither treatment group had a significant impact upon abstinence rates.

Another recent study examined the use of cognitive processing therapy (CPT) for PTSD among Veterans receiving at least one session of CPT in a VA medical center PTSD outpatient clinic [44]. Using a chart review method, this study found a high prevalence (49.3 %) of alcohol use disorder among veterans with PTSD who received CPT. While veterans with co-occurring alcohol use disorder presented with higher PTSD, results indicated no difference in the number of sessions completed or reductions in PTSD or depression symptoms between those with PTSD only and those with co-occurring PTSD and alcohol use disorder.

Preliminary findings in support of Couple Treatment for Alcohol Use Disorder and Posttraumatic Stress Disorder (CTAP) are also promising [45]. CTAP is a 15-session manualized intervention which integrates Behavioral Couples Therapy for alcohol use disorder [46] with cognitive-behavioral conjoint therapy for PTSD [47]. In a recent open-label trial of CTAP among veterans with co-occurring alcohol use disorder and PTSD, participants demonstrated significant reductions in self-, clinician-, and partner-rated PTSD symptoms, depression symptoms, and percentage of heavy drinking days. A larger randomized controlled trial of CTAP is currently underway.

Additional non-exposure-based treatments for co-occurring SUD and PTSD include *Trauma Exposure and Empowerment Model (TREM)* [48], *Transcend* [49], *Addictions and Trauma Recovery Integrated Model (ATRIUM)* [50], *CBT for PTSD* [51], *Substance Dependency Posttraumatic Stress Disorder Therapy* [52], and *Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET)* [53]. While early, mostly uncontrolled trials of these interventions showed promising outcomes, however limited empirical support for these treatments exists. *TREM* was originally developed for women with trauma exposure and comorbid severe mental disorders, including addiction [48]. Amaro and colleagues compared *TREM* (25 sessions) added to a comprehensive treatment package to treatment-as-usual among women ($N = 342$) with trauma history and SUD [54]. Women in *TREM*, as compared to treatment-as-usual, evidenced significantly greater reductions in PTSD symptoms and SUD at the 12-month follow-up. However, because *TREM* was added to a more comprehensive package it is difficult to interpret the results.

Transcend is a 12-session, manualized group treatment initially developed to be part of partial hospitalization programs among veterans. It emphasizes the development of coping skills during the first half of treatment then includes trauma processing during the second half of treatment [49]. During treatment, clinicians encourage 12-step attendance, teach relapse prevention skills, and encourage peer support. In an open study among male Vietnam veterans ($N = 46$) enrolled in a partial hospitalization program, *Transcend* resulted in significant reductions in PTSD symptoms at post-treatment. *Transcend* participants also experienced reductions in alcohol and drug use severity. Although the initial findings were promising, they were uncontrolled and, to our knowledge, were not followed up with a randomized controlled trial.

For a more extensive review of non-exposure-based treatments for co-occurring SUD and PTSD, please refer to Torchalla et al. [55] and van Dam et al. [56]. In addition, Roberts and colleagues recently completed a Cochrane report of 14 randomized clinical trials (1506 participants total) for the treatment of co-occurring SUD and PTSD [57]. They found little evidence to support the use of non-exposure-based group or individual interventions among patients with co-occurring SUD and PTSD. Roberts and colleagues noted that the review is limited by low quality studies and high attrition rates. More rigorously designed trials are clearly needed.

Pharmacologic Interventions

The use of medication to treat SUD and PTSD has largely focused on the treatment of either disorder alone [58]. Recent findings regarding several medications to treat SUD alone, and alcohol use disorders in particular, are encouraging [59–61]. However, one important remaining limitation is that the only FDA-approved medications to treat alcohol use disorders target relapse prevention only. Similar limitations exist with regard to the pharmacologic treatment of PTSD. While many medications have been investigated to treat PTSD [62], only selective serotonin reuptake inhibitors (SSRI) have received FDA approval. Across clinical trials, approximately 20–30% of patients achieve PTSD remission with SSRI treatment [63–66].

In addition to these limitations, there remains a scarcity of outcome data from randomized clinical trials regarding effective medications to treat co-occurring SUD and PTSD. One explanation is that individuals with SUD are often excluded from participation in psychopharmacology trials, both out of concern for patient safety and to maintain sample homogeneity. When a medication has shown efficacy in either or both of these disorders separately and common mechanisms of action have been identified, they are then considered for exploration among those with co-occurring SUD and PTSD.

One encouraging area of progress that has informed efforts to develop effective medications for co-occurring SUD and PTSD is research identifying shared neurobiological underpinnings of these disorders [67]. Neurobiological systems that demonstrate salient and overlapping dysregulation in both SUD and PTSD include the hypothalamic-pituitary-adrenal (HPA) axis and noradrenergic system. Individuals with PTSD have high levels of cerebral spinal fluid corticotropin releasing hormone (CRF) and norepinephrine, which has also been shown to mediate the relationship between stress and substance seeking behavior [68, 69]. Interactions between high CRF and norepinephrine levels might explain why many individuals choose to use substances to self-medicate PTSD symptoms [70]. Furthermore, research indicates that dysregulation of corticolimbic brain circuitry is centrally involved in both SUD and PTSD pathophysiology [71, 72]. Individuals with SUD and PTSD consistently demonstrate lower connectivity in corticolimbic brain regions compared with healthy controls [72–77].

Several different medications have been examined to treat co-occurring SUD and PTSD. Early studies examining the use of noradrenergic reuptake inhibitors (NRIs), selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) in patients with co-occurring SUD and PTSD have had mixed or modest effects, particularly with regard to alcohol use outcomes [26, 70]. Although one study demonstrated greater reductions in heavy alcohol use among patients receiving desipramine (an SNRI) plus naltrexone compared to paroxetine (an SSRI) plus naltrexone. The addition of naltrexone to these common antidepressant medications did not confer any additional treatment benefits [26]. A recent study by Hien and colleagues compared Seeking Safety (SS) with either sertraline (titrated to 200 mg daily) or placebo in a sample of women with co-occurring alcohol use disorder and PTSD [29]. Women randomized to receive SS combined with sertraline had a significantly greater reduction in PTSD symptom severity as measured by the CAPS at the end of treatment than those randomized to receive SS combined with placebo (CAPS reductions of 32.8 versus 16.7 points, respectively; $p < 0.002$). These treatment gains were maintained at 12 months follow-up. No statistically significant group differences emerged with regard to alcohol use outcomes. These results suggest that the combination of a non-exposure-based psychosocial intervention with antidepressant medication was beneficial in the treatment of co-occurring SUD and PTSD.

Medications that target SUD and PTSD concurrently are not only beneficial in preventing PTSD symptom exacerbation but can facilitate engagement in psychosocial treatments, particularly exposure therapies. Naltrexone, an opioid antagonist approved for the treatment of alcohol use disorder, has been used as an adjunct to psychosocial interventions, and combined with other pharmacological agents to reduce cravings and alcohol use [26, 28].

Foa and colleagues examined the use of naltrexone as an adjunct to psychosocial treatment among individuals with co-occurring alcohol use disorder and PTSD [28]. Four groups were examined: PE combined with naltrexone, PE combined with matching placebo, supportive counseling in combined with naltrexone, and supportive counseling combined with matching placebo. All groups had large reductions in percent days drinking, but those randomized to receive naltrexone demonstrated larger reductions in alcohol use than those randomized to receive placebo. There were no significant differences in PTSD symptoms between the treatment groups at post-treatment. However, individuals randomized to receive PE combined with naltrexone had lower PTSD severity at six month follow-up than the other groups. This study demonstrates the potential utility of augmenting exposure-based treatments such as PE with medications such as naltrexone.

Prazosin is an α_1 adrenergic agonist currently FDA-approved for use as a hypertensive agent. Prazosin has been explored in the treatment of SUD and PTSD separately, but only recently in the treatment of co-occurring SUD and PTSD. Prazosin has demonstrated efficacy to reduce PTSD-related nightmares and daytime hyperarousal symptoms, and to improve sleep among individuals with PTSD [27, 78]. Among individuals with single alcohol use disorder diagnosis, prazosin has been shown to reduce alcohol consumption and reduce craving to alcohol cues [79, 80]. In a small randomized controlled trial comparing prazosin to placebo in individuals with co-occurring alcohol use disorder and PTSD, improvements in drinking outcomes favoring prazosin emerged, but no significant between-groups differences were found with regard to PTSD symptoms [81]. However, another recent clinical trial found no advantage of prazosin (16 mg daily) over placebo in reducing PTSD symptoms, sleep disturbances, or drinking outcomes over 12 weeks. These null findings suggest that alcohol consumption may interfere with prazosin's efficacy in improving PTSD symptoms [82]. One commonly noted barrier to treatment adherence in the use of prazosin is the short half-life of the medication. Some patients necessitate multiple daily dosing to achieve their desired dose and thus, medication compliance remains a challenge for some patients. Doxazosin is a longer acting α_1 adrenergic antagonist that can be administered once daily. It is currently being explored among individuals with co-occurring alcohol use disorder and PTSD.

N-acetylcysteine (NAC) is an amino acid derivative supplement used for acetaminophen toxicity and as a mucolytic for chronic pulmonary conditions. NAC restores substance-induced glutamatergic dysregulation and has shown some modest efficacy in reducing cocaine use and craving [83]. In one recent clinical trial, adolescents receiving 1200 mg NAC twice daily were twice as likely to have cannabinoid-free urine drug screens compared to those randomized to receive placebo [84]. Several randomized controlled trials exploring the efficacy of NAC versus placebo in patients with co-occurring SUD and PTSD are currently in progress.

Additional behavioral targets guiding pharmacotherapy development research among individuals with co-occurring SUD and PTSD is emotion dysregulation and fear expression, which are hallmark PTSD symptoms that can be exacerbated by substance use. The neuropeptide oxytocin is a promising candidate to augment psychosocial treatments targeting SUD and PTSD. Higher endogenous oxytocin levels are associated with improved

fear extinction [85, 86], which is a central component of exposure-based therapies for PTSD. Recent studies show that oxytocin reduces substance-related withdrawal, craving, and self-administration [87–90]. Oxytocin also has anxiolytic and fear-modulating effects [86, 91, 92]. Furthermore, recent neuroimaging studies show that oxytocin may mitigate the dysregulation of corticolimbic brain circuitry which is centrally involved in SUD and PTSD pathophysiology [93, 94]. Accumulating literature suggests that combining oxytocin with psychosocial treatments may simultaneously address the neurobiological and psychosocial underpinnings of co-occurring SUD and PTSD, resulting in improved treatment outcomes [39, 89, 95].

Topiramate, a GABA receptor agonist and a glutamate receptor antagonist, has been explored separately in individuals with substance use disorders (alcohol in particular) and PTSD. Only recently has topiramate been examined to target co-occurring alcohol use disorder and PTSD [96–98]. Batki explored the use of topiramate versus placebo in a 12-week randomized control trial in veterans with co-occurring alcohol use disorder and PTSD [99]. Veterans in the topiramate group had fewer standard drinks per week and drinks per drinking day compared to the placebo group, although these reductions were not statistically significant. There was also a greater improvement in PTSD symptom severity in the topiramate versus the placebo group but only at a trend level of statistical significance. Although initial support for use of this medication is promising, the transient learning and memory deficits observed in the veterans taking topiramate may interfere with the efficacy of psychosocial interventions for PTSD [99].

Although the number of ongoing pharmacotherapy trials targeting co-occurring SUD and PTSD continues to increase, existing findings need to be replicated and studies must be conducted among larger samples sizes to validate preliminary safety and efficacy findings. Retention and treatment exposure remain problematic limitations in these studies and longer follow-up periods are indicated as improvement in one disorder may take a longer time to impact the other disorder. Another area to improve upon is the scarcity of studies in civilian populations, where PTSD is often more complex and SUD is often associated with a greater diversity and number of substances used. Finally, studies examining medications to augment evidence-based psychosocial therapies are warranted as combined approaches in other areas of mental health are known to produce enhanced outcomes and are more likely to be used in clinical practice.

Conclusions and Future Directions

Despite the significant distress, impairment, and complicated clinical course facing individuals with co-occurring SUD and PTSD, substantial gaps remain in the literature regarding effective treatment approaches. Recent encouraging advances include the development of integrated psychosocial treatments, and the examination of combined psychosocial and pharmacological approaches to treating the complex presentation of SUD and PTSD. In the future, it is essential to replicate the existing findings.

Another important area for future research is the need to elucidate underlying neurobiological mechanisms of action and moderators of the various integrated and

combined interventions. These factors may serve as prognostic and diagnostic indicators of pathophysiology and treatment outcome in co-occurring SUD and PTSD. Structural and functional neuroimaging approaches are one such unique opportunity to achieve that goal. For example, some literature suggests that some patients may benefit from the use of cognitive training tasks to enhance cognitive control functioning in the prefrontal cortex prior to engaging in psychosocial treatments. Some investigators have proposed that cognitive training might help mitigate prefrontal cortex hypoactivity observed in co-occurring SUD and PTSD by training neurocircuits to perform at a level of cognitive control needed for one to receive the greatest benefit from the treatment [100].

Acknowledgments

This manuscript is the result of work supported, in part, by the National Institute on Child Health and Human Development and the Office of Research on Women's Health (K12HD055885) and the National Institute of Alcohol Abuse and Alcoholism (T32AA007474).

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. Driessen M, Schulte S, Luedecke C, Schaefer I, Sutmann F, Ohlmeier M, et al. Trauma and PTSD in patients with alcohol, drug, or dual dependence: a multi-center study. *Alcohol Clin Exp Res.* 2008; 32(3):481–488. [PubMed: 18215214]
2. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *J Anxiety Disord.* 2011; 25(3):456–465. [PubMed: 21168991]
3. Mills KL, Teesson M, Ross J, Peters L. Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being. *Am J Psychiatr.* 2006; 163(4): 652–658. [PubMed: 16585440]
4. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *Int J Methods Psychiatr Res.* 2012; 21:169–184. [PubMed: 22865617]
5. Blanco C, Xu Y, Brady KT, Pérez-Fuentes G, Okuda M, Wang S. Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from National Epidemiological Survey on Alcohol and Related Conditions. *Drug Alcohol Depend.* 2013; 132(3):630–638. [PubMed: 23702490]
6. Petrakis IL, Rosenheck R, Desai R. Substance use comorbidity among veterans with posttraumatic stress disorder and other psychiatric illness. *Am J Addict.* 2011; 20(3):185–189. [PubMed: 21477045]
7. Pietrzak RH, Goldstein MB, Malley JC, Johnson DC, Southwick SM. Subsyndromal posttraumatic stress disorder is associated with health and psychosocial difficulties in veterans of Operations Enduring Freedom and Iraqi Freedom. *Depression Anxiety.* 2009; 26(8):739–744. [PubMed: 19496075]
8. Marx BP, Brailey K, Proctor SP, MacDonald HZ, Graefe AC, Amoroso P, et al. Association of time since deployment, combat intensity, and posttraumatic stress symptoms with neuropsychological outcomes following Iraq War deployment. *Arch Gen Psychiatry.* 2009; 66:996–1004. [PubMed: 19736356]
9. Ouimette PC, Moos RH, Finney JW. PTSD treatment and 5-year remission among patients with substance use and posttraumatic stress disorders. *J Consult Clin Psychol.* 2003; 71(2):410. [PubMed: 12699036]

10. Hawkins EJ, Malte CA, Baer JS, Kivlahan DR. Prevalence, predictors, and service utilization of patients with recurrent use of Veterans Affairs substance use disorder specialty care. *J Subst Abuse Treat.* 2012; 43(2):221–230. [PubMed: 22197302]
11. Kaier E, Possemato K, Lantinga LJ, Maisto SA, Ouimette PC. Associations between PTSD and healthcare utilization among OEF/OIF veterans with hazardous alcohol use. *Traumatology.* 2014; 20(3):142.
12. Bowe A, Rosenheck R. PTSD and substance use disorder among veterans: characteristics, service utilization and pharmacotherapy. *J Dual Diagn.* 2015; 11(1):22–32. [PubMed: 25513763]
13. Stewart, SH.; Conrod, PJ. Trauma and substance abuse: causes, consequences, and treatment of comorbid disorders. Washington, DC: American Psychological Association; 2003. Psychosocial models of functional associations between posttraumatic stress disorder and substance use disorder.
14. Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, et al. Prevalence and treatment of mental disorders, 1990 to 2003. *N Engl J Med.* 2005; 352(24):2515–2523. [PubMed: 15958807]
15. Ouimette PC, Read JP, Wade M, Tirone V. Modeling associations between posttraumatic stress symptoms and substance use. *Addict Behav.* 2010; 35(1):64–67. [PubMed: 19729250]
16. Leeies M, Pagura J, Sareen J, Bolton JM. The use of alcohol and drugs to self-medicate symptoms of posttraumatic stress disorder. *Depression anxiety.* 2010; 27:731–736. [PubMed: 20186981]
17. Logrip ML, Zorrilla EP, Koob GF. Stress modulation of drug self-administration: implications for addiction comorbidity with posttraumatic stress disorder. *Neuropharmacology.* 2012; 62(2):552–564. [PubMed: 21782834]
18. Back SE, Waldrop AE, Brady KT. Treatment challenges associated with comorbid substance use and posttraumatic stress disorder: clinicians' perspectives. *Am J Addict.* 2009; 18(1):15–20. [PubMed: 19219661]
19. Back SE, Brady KT, Sonne SC, Verduin ML. Symptom improvement in co-occurring PTSD and alcohol dependence. *J Nerv Ment Dis.* 2006; 194(9):690–696. [PubMed: 16971821]
20. Back SE, Waldrop AE, Brady KT, Hien D. Evidenced-based time-limited treatment of co-occurring substance-use disorders and civilian-related posttraumatic stress disorder. *Brief Treat Crisis Interv.* 2006; 6(4):283.
21. Najavits LM, Weiss RD, Liese BS. Group cognitive-behavioral therapy for women with PTSD and substance use disorder. *J Subst Abuse Treat.* 1996; 13(1):13–22.
22. Najavits LM, Sullivan TP, Schmitz M, Weiss RD, Lee CS. Treatment utilization by women with PTSD and substance dependence. *Am J Addict.* 2004; 13(3):215–224. [PubMed: 15370941]
23. Brown PJ, Stout RL, Gannon-Rowley J. 15 substance use disorder-PTSD comorbidity: patients' perceptions of symptom interplay and treatment issues. *J Subst Abuse Treat.* 1998; 15(5):445–448.
24. Mills KL, Teesson M, Back SE, Brady KT, Baker AL, Hopwood S, et al. Integrated exposure-based therapy for co-occurring post-traumatic stress disorder and substance dependence—a randomized controlled trial exposure therapy for PTSD and substance dependence. *JAMA.* 2012; 308(7):690–699. [PubMed: 22893166] This is the first published randomized controlled trial examining the efficacy of COPE, a novel integrated treatment for PTSD and substance use disorders.
25. Hien DA, Cohen LR, Miele GM, Litt LC, Capstick C. Promising treatments for women with comorbid PTSD and substance use disorders. *Am J Psychiatr.* 2004; 161(8):1426–1432. [PubMed: 15285969]
26. Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, et al. Noradrenergic vs. serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. *Neuropsychopharmacology.* 2012; 37(4):996–1004. [PubMed: 22089316]
27. Raskind MA. Prazosin for the treatment of PTSD. *Current Treat Options in Psychiatr.* 2015; 2(2): 192–203.
28. Foa EB, Yuskov DA, McLean CP, Suvak MK, Bux DA, Oslin D, et al. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. *JAMA.* 2013; 310(5):488–495. [PubMed: 23925619]

29. Hien DA, Levin FR, Ruglass LM, López-Castro T, Papini S, Hu M, et al. Combining seeking safety with sertraline for PTSD and alcohol use disorders: a randomized controlled trial. *J Consult Clin Psychol.* 2015; 83(2):359. [PubMed: 25622199]
30. Foa, EB.; Hembree, EA.; Rothbaum, BO. Prolonged exposure therapy for PTSD: emotional processing of traumatic experiences therapist guide. Oxford University Press; 2007.
31. Rothbaum BO, Astin MC, Marsteller F. Prolonged exposure versus eye movement desensitization and reprocessing (EMDR) for PTSD rape victims. *J Trauma Stress.* 2005; 18(6):607–616. [PubMed: 16382428]
32. Marks I, Lovell K, Noshirvani H, Livanou M, Thrasher S. Treatment of posttraumatic stress disorder by exposure and/or cognitive restructuring: a controlled study. *Arch Gen Psychiatry.* 1998; 55(4):317–325. [PubMed: 9554427]
33. Foa EB, Rothbaum BO, Riggs DS, Murdock TB. Treatment of posttraumatic stress disorder in rape victims: a comparison between cognitive-behavioral procedures and counseling. *J Consult Clin Psychol.* 1991; 59(5):715. [PubMed: 1955605]
34. Schnurr PP, Friedman MJ, Engel CC, Foa EB, Shea MT, Chow BK. Cognitive behavioral therapy for posttraumatic stress disorder in women: a randomized controlled trial. *J Am Med Assoc.* 2007; 297:820–830.
35. Pacella ML, Armelie A, Boarts J, Wagner G, Jones T, Feeny N, et al. The impact of prolonged exposure on PTSD symptoms and associated psychopathology in people living with HIV: a randomized test of concept. *AIDS Behav.* 2012; 16(5):1327–1340. [PubMed: 22012149]
36. Back, SE.; Foa, EBTK.; Mills, K.; Teesson, M.; Carroll, K. Treatments that work. New York, New York: Oxford University Press; 2015. Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE). Therapist manual.
37. Back SE, Killeen TK, Foa EB, Santa Ana EJ, Gros DF, Brady KT. Use of an integrated therapy with prolonged exposure to treat PTSD and comorbid alcohol dependence in an Iraq veteran. *Am J Psychiatr.* 2012; 169(7):688–697. [PubMed: 22760188]
38. Carroll, KM. A cognitive behavioral approach: treating cocaine addiction. MD: National Institute on Drug Abuse Rockville; 1998.
39. Badour CL, Flanagan JC, Gros DF, Killeen TK, Pericot-Valverde I, Back SE. Habituation of fear and substance use craving as predictors of symptom change among patients with co-occurring PTSD and alcohol use disorders receiving Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE). Under review. This study demonstrates mechanisms of change during treatment in an RCT testing an integrated treatment for PTSD and substance use disorder among Veterans.
40. Nace, EP. Recent developments in alcoholism. Springer; 1988. Posttraumatic stress disorder and substance abuse clinical issues; p. 9-26.
41. Pitman RK, Altman B, Greenwald E, Longpre RE, Macklin ML, Poire RE, et al. Psychiatric complications during flooding therapy for posttraumatic stress disorder. *Journal of Clinical Psychiatry.* 1991
42. Najavits LM, Weiss RD, Shaw SR, Muenz LR. “Seeking Safety”: outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence. *J Trauma Stress.* 1998; 11(3):437–456. [PubMed: 9690186]
43. Hien DA, Wells EA, Jiang H, Suarez-Morales L, Campbell ANC, Cohen LR, et al. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. *J Consult Clin Psychol.* 2009; 77(4):607. [PubMed: 19634955] This is the first multisite RCT comparing efficacy of Seeking Safety with an active comparison group among women with co-occurring PTSD and substance use disorder.
44. Kaysen D, Schumm JA, Pedersen ER, Seim RW, Bedard-Gilligan M, Chard KM. Cognitive processing therapy for veterans with comorbid PTSD and alcohol use disorders. *Addict Behav.* 2014; 39(2):420–427. [PubMed: 24035644]
45. Schumm JA, Monson CM, O’Farrell TJ, Gustin NG, Chard KM. Couple treatment for alcohol use disorder and posttraumatic stress disorder: pilot results from US military veterans and their partners. *J Trauma Stress.* 2015; 28(3):247–252. [PubMed: 25965768]

46. O'Farrell, TJ.; Fals-Stewart, W. Behavioral couples therapy for alcoholism and drug abuse. Guilford Press; 2013.
47. Monson, CM.; Fredman, SJ. Cognitive-behavioral conjoint therapy for posttraumatic stress disorder: therapist's manual. New York, NY: Guilford Press; 2012.
48. Harris, M. Trauma recovery and empowerment: a clinician's guide for working with women in groups. New York: The Free Press; 1998.
49. Donovan B, Padin-Rivera E, Kowaliw S. "Transcend": initial outcomes from a posttraumatic stress disorder/substance abuse treatment program. *J Trauma Stress*. 2001; 14(4):757–772. [PubMed: 11776422]
50. Miller, D.; Guidry, L. Addictions and trauma recovery: healing the body, mind and spirit. WW Norton & Co; 2001.
51. McGovern MP, Lambert-Harris C, Acquilano S, Xie H, Alterman AI, Weiss RD. A cognitive behavioral therapy for co-occurring substance use and posttraumatic stress disorders. *Addict Behav*. 2009; 34(10):892–897. [PubMed: 19395179]
52. Triffleman E, Carroll K, Kellogg S. Substance dependence post-traumatic stress disorder therapy: an integrated cognitive-behavioral approach. *J Subst Abus Treat*. 1999; 17(1):3–14.
53. Ford JD, Russo E. Trauma-focused, present-centered, emotional self-regulation approach to integrated treatment for posttraumatic stress and addiction: trauma adaptive recovery group education and therapy (TARGET). *American Journal of Psychotherapy*. 2006; 60(4)
54. Amaro H, Chernoff M, Brown V, Arévalo S, Gatz M. Does integrated trauma-informed substance abuse treatment increase treatment retention? *J Community Psychol*. 2007; 35(7):845–862.
55. Torchalla I, Nosen L, Rostam H, Allen P. Integrated treatment programs for individuals with concurrent substance use disorders and trauma experiences: a systematic review and meta-analysis. *J Subst Abus Treat*. 2012; 42(1):65–77.
56. van Dam D, Vedel E, Ehring T, Emmelkamp P. Psychological treatments for concurrent posttraumatic stress disorder and substance use disorder: a systematic review. *Clin Psychol Rev*. 2012; 32(3):202–214. [PubMed: 22406920]
57. Roberts NP, Roberts PA, Jones N, Bisson JI. Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder: a systematic review and meta-analysis. *Clin Psychol Rev*. 2015; 38:25–38. [PubMed: 25792193]
58. Rubinsky AD, Chen C, Batki SL, Williams EC, Harris A. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among US Veterans Health Administration patients with dual diagnoses. *J Psychiatr Res*. 2015; 69:150–157. [PubMed: 26343607]
59. Berglund M, Thelander S, Salaspuro M, Franck J, Andréasson S, Öjehagen A. Treatment of alcohol abuse: an evidence-based review. *Alcohol Clin Exp Res*. 2003; 27(10):1645–1656. [PubMed: 14574236]
60. Chick J, Leher P, Landron F. Does acamprosate improve reduction of drinking as well as aiding abstinence? *J Psychopharmacol*. 2003; 17(4):397–402. [PubMed: 14870951]
61. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? *Addiction*. 2013; 108(2):275–293. [PubMed: 23075288]
62. Steckler T, Risbrough V. Pharmacological treatment of PTSD— established and new approaches. *Neuropharmacology*. 2012; 62(2):617–627. [PubMed: 21736888]
63. Davidson JT, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. *Arch Gen Psychiatry*. 2001; 58(5):485–492. [PubMed: 11343529]
64. Brady KT, Pearlstein T, Asnis GM, Baker DG, Rothbaum BO, Sikes CR, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. *JAMA*. 2000; 283(14):1837–1844. [PubMed: 10770145]
65. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of posttraumatic stress disorder (PTSD). *Int J Neuropsychopharmacol*. 2012; 15(6):825–840. [PubMed: 21798109]
66. Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. *CNS Spectrums*. 2009; 14(1):25–31. [PubMed: 19169191]

67. Sofuoglu M, Rosenheck R, Petrakis IL. Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress. *Addict Behav.* 2014; 39(2):428–433. [PubMed: 24035645]
68. Bremner JD, Innis RB, Ng CK, Staib LH, Salomon RM, Bronen RA, et al. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. *Arch Gen Psychiatry.* 1997; 54(3):246–254. [PubMed: 9075465]
69. Baker DG, West SA, Nicholson WE, Ekhtor NN, Kasckow JW, Hill KK, et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. *American Journal of Psychiatry.* 1999
70. Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. *Am J Psychiatr.* 2005; 162(8):1483–1493. [PubMed: 16055769]
71. Shin LM, Rauch SL, Pitman RK. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. *Ann N Y Acad Sci.* 2006; 1071(1):67–79. [PubMed: 16891563]
72. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. *Nat Rev Neurosci.* 2011; 12(11):652–669. [PubMed: 22011681]
73. Rabinak CA, Angstadt M, Welsh RC, Kenndy AE, Lyubkin M, Martis B, et al. Altered amygdala resting-state functional connectivity in post-traumatic stress disorder. *Frontiers in psychiatry.* 2011; 2
74. Stevens JS, Jovanovic T, Fani N, Ely TD, Glover EM, Bradley B, et al. Disrupted amygdala-prefrontal functional connectivity in civilian women with posttraumatic stress disorder. *J Psychiatr Res.* 2013; 47(10):1469–1478. [PubMed: 23827769]
75. Brown VM, LaBar KS, Haswell CC, Gold AL, Beall SK, Van Voorhees E, et al. Altered resting-state functional connectivity of basolateral and centromedial amygdala complexes in posttraumatic stress disorder. *Neuropsychopharmacology.* 2013; 39(2):361–369.
76. Beck A, Wüstenberg T, Genauck A, Wrase J, Schlagenhauf F, Smolka MN, et al. Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. *Arch Gen Psychiatry.* 2012; 69(8):842–852. [PubMed: 22868938]
77. Gorka SM, Fitzgerald DA, King AC, Phan KL. Alcohol attenuates amygdala–frontal connectivity during processing social signals in heavy social drinkers. *Psychopharmacology.* 2013; 229(1):141–154. [PubMed: 23584670]
78. Khachatryan D, Groll D, Booij L, Sepehry AA, Schütz CG. Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials. *General Hospital Psychiatry.* 2015
79. Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. *Alcohol Clin Exp Res.* 2009; 33(2):255–263. [PubMed: 18945226]
80. Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, et al. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. *Alcohol Clin Exp Res.* 2012; 36(2):351–360. [PubMed: 21919922]
81. Simpson TL, Malte CA, Dietel B, Tell D, Pocock I, Lyons R, et al. A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. *Alcohol Clin Exp Res.* 2015; 39(5):808–817. [PubMed: 25827659]
82. Petrakis IL, Desai N, Gueorguieva R, Arias AJ, O'Brien E, Jane JS, et al. Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial. *Alcohol Clin Exp Res.* 2016; 40(1):178–186. [PubMed: 26683790] This rigorous RCT yielded null findings for prazosin's efficacy in treating comorbid PTSD and alcohol use disorder, indicating that comorbidity may impact prazosin's efficacy.
83. Brown RM, Kupchik YM, Kalivas PW. The story of glutamate in drug addiction and of N-acetylcysteine as a potential pharmacotherapy. *JAMA psychiatr.* 2013; 70(9):895–897.
84. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. *American Journal of Psychiatry.* 2012

85. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. *J Neurosci*. 2005; 25(49):11489–11493. [PubMed: 16339042]
86. Eckstein M, Becker B, Scheele D, Scholz C, Preckel K, Schlaepfer TE, et al. Oxytocin facilitates the extinction of conditioned fear in humans. *Biol Psychiatry*. 2014; 78(3):194–202. [PubMed: 25542304]
87. McRae-Clark AL, Baker NL, Moran-Santa Maria M, Brady KT. Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. *Psychopharmacology*. 2013; 228(4):1–9. [PubMed: 23649885]
88. Carson DS, Hunt GE, Guastella AJ, Barber L, Cornish JL, Arnold JC, et al. Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. *Addict Biol*. 2010; 15(4):448–463. [PubMed: 20731630]
89. McGregor IS, Bowen MT. Breaking the loop: oxytocin as a potential treatment for drug addiction. *Horm Behav*. 2012; 61(3):331–339. [PubMed: 22198308]
90. Pedersen CA, Smedley KL, Leserman J, Jarskog LF, Rau SW, Kampov-Polevoi A, et al. Intranasal oxytocin blocks alcohol withdrawal in human subjects. *Alcohol Clin Exp Res*. 2013; 37(3):484–489. [PubMed: 23025690]
91. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. *Biol Psychiatry*. 2003; 54(12):1389–1398. [PubMed: 14675803]
92. Gorka SM, Fitzgerald DA, Labuschagne I, Hosanagar A, Wood AG, Nathan PJ, et al. Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder. *Neuropsychopharmacology*. 2015; 40(2):278–286. [PubMed: 24998619]
93. Dodhia S, Hosanagar A, Fitzgerald DA, Labuschagne I, Wood AG, Nathan PJ, et al. Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder. *Neuropsychopharmacology*. 2014; 39:2061–2069. [PubMed: 24594871]
94. Sripada CS, Phan KL, Labuschagne I, Welsh RC, Nathan PJ, Wood AG. Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. *Int J Neuropsychopharmacol*. 2013; 16(2):255–260. [PubMed: 22647521]
95. Olf M, Langeland W, Witteveen A, Denys D. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. *CNS Spectrums*. 2010; 15(8):522–530. [PubMed: 20703199]
96. Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. *Alcohol Clin Exp Res*. 2014; 38(6):1481–1488. [PubMed: 24796492]
97. Johnson BA, Ait-Daoud N, Wang X, Penberthy JK, Javors MA, Seneviratne C, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. *JAMA Psychiatr*. 2013; 70(12):1338–1346.
98. Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. *J Clin Psychiatr*. 2013; 74(6):1,478–550.
99. Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop AE, et al. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. *Alcohol Clin Exp Res*. 2014; 38(8):2169–2177. [PubMed: 25092377]
100. McClure SM, Bickel WK. A dual-systems perspective on addiction: contributions from neuroimaging and cognitive training. *Ann N Y Acad Sci*. 2014; 1327(1):62–78. [PubMed: 25336389]